Downregulation of BCL2 by AT-101 enhances the antileukaemic effect of lenalidomide both by an immune dependant and independent manner

Aisha Masood, Kasyapa Chitta, Aneel Paulus, A. Nazmul H Khan, Taimur Sher, Noreen Ersing, Kena C. Miller, Deborah Manfredi, Sikander Ailawadhi, Ivan M Borrello, Kelvin P. Lee, Asher A. Chanan-Khan

Research output: Contribution to journalArticle

Abstract

Over-expression of anti-apoptotic BCL2 has been reported in chronic lymphocytic leukaemia (CLL), but targeting BCL2 alone did not yield appreciable clinical results. However, it was demonstrated that BCL2 inhibitors enhanced the clinical efficacy of chemo and immunotherapeutics. Lenalidomide, an immunomodulator, is clinically effective in CLL and can enhance the anti-CLL effects of CD20 targeting monoclonal antibody, rituximab. Here, we investigated the mechanism of immune-directed killing of lenalidomide in CLL and evaluated if concurrent targeting of CD20 and BCL2 can enhance this effect. In vitro treatment with lenalidomide enhanced the antibody-mediated cellular cytotoxicity (ADCC) directed by rituximab in autologous leukaemic cells. Furthermore, peripheral blood mononuclear cells obtained from patients after treatment with lenalidomide and rituximab showed increased ADCC in vitro versus control (pre-treatment sample). This effect was further enhanced with pre-treatment of tumour cells with AT-101 (a BH3 mimetic that functions as BCL2 antagonist). Our data suggest that AT-101 in combination with lenalidomide can potentially be an effective therapeutic regimen for CLL.

Original languageEnglish (US)
Pages (from-to)59-66
Number of pages8
JournalBritish Journal of Haematology
Volume157
Issue number1
DOIs
StatePublished - Apr 2012

Fingerprint

B-Cell Chronic Lymphocytic Leukemia
Down-Regulation
Therapeutics
Antibodies
Immunologic Factors
Blood Cells
Monoclonal Antibodies
gossypol acetic acid
lenalidomide
Rituximab
Neoplasms
In Vitro Techniques

Keywords

  • Antibody-mediated cellular cytotoxicity
  • AT-101
  • CD20
  • Chronic lymphocytic leukaemia
  • Lenalidomide

ASJC Scopus subject areas

  • Hematology

Cite this

Downregulation of BCL2 by AT-101 enhances the antileukaemic effect of lenalidomide both by an immune dependant and independent manner. / Masood, Aisha; Chitta, Kasyapa; Paulus, Aneel; Khan, A. Nazmul H; Sher, Taimur; Ersing, Noreen; Miller, Kena C.; Manfredi, Deborah; Ailawadhi, Sikander; Borrello, Ivan M; Lee, Kelvin P.; Chanan-Khan, Asher A.

In: British Journal of Haematology, Vol. 157, No. 1, 04.2012, p. 59-66.

Research output: Contribution to journalArticle

Masood, A, Chitta, K, Paulus, A, Khan, ANH, Sher, T, Ersing, N, Miller, KC, Manfredi, D, Ailawadhi, S, Borrello, IM, Lee, KP & Chanan-Khan, AA 2012, 'Downregulation of BCL2 by AT-101 enhances the antileukaemic effect of lenalidomide both by an immune dependant and independent manner', British Journal of Haematology, vol. 157, no. 1, pp. 59-66. https://doi.org/10.1111/j.1365-2141.2011.08984.x
Masood, Aisha ; Chitta, Kasyapa ; Paulus, Aneel ; Khan, A. Nazmul H ; Sher, Taimur ; Ersing, Noreen ; Miller, Kena C. ; Manfredi, Deborah ; Ailawadhi, Sikander ; Borrello, Ivan M ; Lee, Kelvin P. ; Chanan-Khan, Asher A. / Downregulation of BCL2 by AT-101 enhances the antileukaemic effect of lenalidomide both by an immune dependant and independent manner. In: British Journal of Haematology. 2012 ; Vol. 157, No. 1. pp. 59-66.
@article{127c57daab8b421ca6254a9a751eb936,
title = "Downregulation of BCL2 by AT-101 enhances the antileukaemic effect of lenalidomide both by an immune dependant and independent manner",
abstract = "Over-expression of anti-apoptotic BCL2 has been reported in chronic lymphocytic leukaemia (CLL), but targeting BCL2 alone did not yield appreciable clinical results. However, it was demonstrated that BCL2 inhibitors enhanced the clinical efficacy of chemo and immunotherapeutics. Lenalidomide, an immunomodulator, is clinically effective in CLL and can enhance the anti-CLL effects of CD20 targeting monoclonal antibody, rituximab. Here, we investigated the mechanism of immune-directed killing of lenalidomide in CLL and evaluated if concurrent targeting of CD20 and BCL2 can enhance this effect. In vitro treatment with lenalidomide enhanced the antibody-mediated cellular cytotoxicity (ADCC) directed by rituximab in autologous leukaemic cells. Furthermore, peripheral blood mononuclear cells obtained from patients after treatment with lenalidomide and rituximab showed increased ADCC in vitro versus control (pre-treatment sample). This effect was further enhanced with pre-treatment of tumour cells with AT-101 (a BH3 mimetic that functions as BCL2 antagonist). Our data suggest that AT-101 in combination with lenalidomide can potentially be an effective therapeutic regimen for CLL.",
keywords = "Antibody-mediated cellular cytotoxicity, AT-101, CD20, Chronic lymphocytic leukaemia, Lenalidomide",
author = "Aisha Masood and Kasyapa Chitta and Aneel Paulus and Khan, {A. Nazmul H} and Taimur Sher and Noreen Ersing and Miller, {Kena C.} and Deborah Manfredi and Sikander Ailawadhi and Borrello, {Ivan M} and Lee, {Kelvin P.} and Chanan-Khan, {Asher A.}",
year = "2012",
month = "4",
doi = "10.1111/j.1365-2141.2011.08984.x",
language = "English (US)",
volume = "157",
pages = "59--66",
journal = "British Journal of Haematology",
issn = "0007-1048",
publisher = "Wiley-Blackwell",
number = "1",

}

TY - JOUR

T1 - Downregulation of BCL2 by AT-101 enhances the antileukaemic effect of lenalidomide both by an immune dependant and independent manner

AU - Masood, Aisha

AU - Chitta, Kasyapa

AU - Paulus, Aneel

AU - Khan, A. Nazmul H

AU - Sher, Taimur

AU - Ersing, Noreen

AU - Miller, Kena C.

AU - Manfredi, Deborah

AU - Ailawadhi, Sikander

AU - Borrello, Ivan M

AU - Lee, Kelvin P.

AU - Chanan-Khan, Asher A.

PY - 2012/4

Y1 - 2012/4

N2 - Over-expression of anti-apoptotic BCL2 has been reported in chronic lymphocytic leukaemia (CLL), but targeting BCL2 alone did not yield appreciable clinical results. However, it was demonstrated that BCL2 inhibitors enhanced the clinical efficacy of chemo and immunotherapeutics. Lenalidomide, an immunomodulator, is clinically effective in CLL and can enhance the anti-CLL effects of CD20 targeting monoclonal antibody, rituximab. Here, we investigated the mechanism of immune-directed killing of lenalidomide in CLL and evaluated if concurrent targeting of CD20 and BCL2 can enhance this effect. In vitro treatment with lenalidomide enhanced the antibody-mediated cellular cytotoxicity (ADCC) directed by rituximab in autologous leukaemic cells. Furthermore, peripheral blood mononuclear cells obtained from patients after treatment with lenalidomide and rituximab showed increased ADCC in vitro versus control (pre-treatment sample). This effect was further enhanced with pre-treatment of tumour cells with AT-101 (a BH3 mimetic that functions as BCL2 antagonist). Our data suggest that AT-101 in combination with lenalidomide can potentially be an effective therapeutic regimen for CLL.

AB - Over-expression of anti-apoptotic BCL2 has been reported in chronic lymphocytic leukaemia (CLL), but targeting BCL2 alone did not yield appreciable clinical results. However, it was demonstrated that BCL2 inhibitors enhanced the clinical efficacy of chemo and immunotherapeutics. Lenalidomide, an immunomodulator, is clinically effective in CLL and can enhance the anti-CLL effects of CD20 targeting monoclonal antibody, rituximab. Here, we investigated the mechanism of immune-directed killing of lenalidomide in CLL and evaluated if concurrent targeting of CD20 and BCL2 can enhance this effect. In vitro treatment with lenalidomide enhanced the antibody-mediated cellular cytotoxicity (ADCC) directed by rituximab in autologous leukaemic cells. Furthermore, peripheral blood mononuclear cells obtained from patients after treatment with lenalidomide and rituximab showed increased ADCC in vitro versus control (pre-treatment sample). This effect was further enhanced with pre-treatment of tumour cells with AT-101 (a BH3 mimetic that functions as BCL2 antagonist). Our data suggest that AT-101 in combination with lenalidomide can potentially be an effective therapeutic regimen for CLL.

KW - Antibody-mediated cellular cytotoxicity

KW - AT-101

KW - CD20

KW - Chronic lymphocytic leukaemia

KW - Lenalidomide

UR - http://www.scopus.com/inward/record.url?scp=84858299100&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84858299100&partnerID=8YFLogxK

U2 - 10.1111/j.1365-2141.2011.08984.x

DO - 10.1111/j.1365-2141.2011.08984.x

M3 - Article

C2 - 22171982

AN - SCOPUS:84858299100

VL - 157

SP - 59

EP - 66

JO - British Journal of Haematology

JF - British Journal of Haematology

SN - 0007-1048

IS - 1

ER -